Exclusive: Inside $3.8B @chaidiscovery After leaving OpenAI & Stripe, co-founders Josh Meier (@joshim5) and Jack Dent (@jackdent) built a pioneering AI drug design model called Chai-1. Now? Their models are used by giants like Eli Lilly, Pfizer and Novartis. Their models design antibodies in hours, not years - with atomic-level accuracy confirmed in the lab. If they're right, we're closer than ever to curing complex diseases. We went to San Francisco to find out. They've raised $600M + from @saranormous @lachygroom @FEhrsam @ThriveCapital @sequoia @generalcatalyst @OpenAI @MenloVentures @IndexVentures @kleinerperkins + more. 0:00 AI drug design - how is it possible? 1:32 Josh: Leaving OpenAI for biology 2:34 90% of drugs used to fail 3:24 An outside scientist's honest take 4:40 Chai-3: Drug design in hours not years 5:30 Why Eli Lilly bet on Chai 6:20 When will this reach patients? 8:56 A hopeful future: Alzheimer's & aging